Sign in
WithdrawnPhase 3

Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC

Key facts

Who runs it
Eurofarma Laboratorios S.A.
Where
Brazil6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 3
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Nexium®
  • Esomeprazol (40mg) + Sodium Bicarbonate (721mg)
Record updated
1 April 2025
Why it stopped
Change company strategy

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • ICF signing
  • Age ≥ 18 years
  • Gastroesophageal reflux disease diagnosis
  • Grade 0 to grade III reflux esophagitis, assessed by means of upper gastrointestinal endoscopy
  • Ability to have the endoscopy, pH-metry and esophageal manometry examinations performed
  • Washout period of 1 week without using PPI, H2 antagonists and prokinetic agents and of at least 1 day without using antacids

Who cannot take part

  • Previous gastric or esophageal surgery
  • Concomitant diseases, such as kidney, liver and heart failure
  • Abusive drug or alcohol use
  • Treatment with PPI, H2 antagonists or prokinetic agents that may not be withheld during the washout period of 1 week or during the study
  • Use of nonsteroidal anti-inflammatory drugs (NSAIDs), antiemetic agents, macrolide antibiotics and systemic corticoids for a period equal to or greater than 2 weeks before the study or that is expected to require prolonged use during study treatment
  • Concomitant use or requirement of a gastric pH-dependent medication for optimal absorption
  • Scheduled use of other medications metabolized by cytochrome CYP during the study
  • Suspected or confirmed cancer of any type
  • Intolerance or allergy to any of the components in the drug products assessed in the study
  • History of active peptic ulcer
  • Dietary sodium restriction, metabolic alkalosis, hypokalemia, Barter syndrome; Pregnancy or breastfeeding
  • Abnormal values for white blood cells, platelets or hemoglobin
  • Significant changes in serum sodium, potassium, calcium or creatinine concentrations
  • Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency
  • Presence of esophagitis requiring intervention (grade IV), esophageal varices, Barrett's esophagus, systemic sclerosis or ulcers (gastric or duodenal ulcers)
  • Recent participation (within the last 12 months) in another clinical study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A phase III, randomized, open-label, superiority study comparing the incremental product esomeprazole associated with sodium bicarbonate made by Eurofarma and Nexium® in the treatment of gastroesophageal reflux disease. The study will enroll 94 patients in each arm (total of 188 patients).

The 2 groups in the trial

  • Esomeprazole (40mg) + Sodium Bicarbonate (721mg)Treatment being tested

    Treatment: Esomeprazol (40mg) + Sodium Bicarbonate (721mg)

  • Nexium®Existing treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Randomized, Open-label, Superiority Study Comparing the Incremental Product Esomeprazole Associated With Sodium Bicarbonate Made by Eurofarma and Nexium® in the Treatment of Gastroesophageal Reflux Disease
Record updated
1 April 2025